Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial (HALT-C)
Brief Summary: The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated interferon) in patients who failed to respond to prior interferon treatment. All patients who enter the trial will be treated for 6 months with Peginterferon alfa-2a and Ribavirin. Patients who respond to this 6 month treatment will continue to be treated for an additional 6 months.

Patients who do not respond to this treatment will be eligible for the long-term maintenance phase of this study where patients will be randomly selected to be treated with Peginterferon alfa-2a or to discontinue treatment for 3.5 years. Patients in both arms of this study will be followed closely with quarterly study visits.

The combination of peginterferon plus ribavirin has recently been approved by the FDA for treatment of chronic hepatitis C. Patients who remain HCV-RNA positive after being treated for at least 6 months with peginterferon and ribavirin outside of this study may be eligible to directly enter the randomized portion of the HALT-C Trial.

The HALT-C study is designed to determine if continuing interferon long-term over several years will suppress Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation.


Options:
A: Arm Label: PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a, Drug: Placebo | Arm Label: Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a, Drug: Telaprevir | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a, Drug: Telaprevir | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a 12 Week; Type: EXPERIMENTAL; Interventions: Drug: Pegylated Interferon Alfa 2a, Drug: Telaprevir | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week | Intervention Type: DRUG; Name: Pegylated Interferon Alfa 2a; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a 12 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a 12 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Peginterferon alfa-2a + Ribavirin, Drug: Peginterferon alfa-2a | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Peginterferon alfa-2a + Ribavirin | Intervention Type: DRUG; Name: Peginterferon alfa-2a + Ribavirin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Peginterferon alfa-2a; Assigned to Arm(s): 1
C: Arm Label: PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a, Other: Placebo | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a | Arm Label: Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week | Intervention Type: DRUG; Name: Pegylated Interferon Alfa 2a; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week
D: Arm Label: Pegylated-interferon Alfa-2a + Ribavirin (Group A); Type: EXPERIMENTAL; Interventions: Drug: Pegylated-interferon Alfa-2a, Drug: Ribavirin | Arm Label: Pegylated-interferon Alfa-2a + Ribavirin (Group B); Type: EXPERIMENTAL; Interventions: Drug: Pegylated-interferon Alfa-2a, Drug: Ribavirin | Arm Label: Pegylated-interferon Alfa-2a + Ribavirin (Group C); Type: EXPERIMENTAL; Interventions: Drug: Pegylated-interferon Alfa-2a, Drug: Ribavirin | Arm Label: Pegylated-interferon Alfa-2a + Ribavirin (Group D); Type: EXPERIMENTAL; Interventions: Drug: Pegylated-interferon Alfa-2a, Drug: Ribavirin | Arm Label: Pegylated-interferon Alfa-2a + Ribavirin (Group E); Type: EXPERIMENTAL; Interventions: Drug: Pegylated-interferon Alfa-2a, Drug: Ribavirin | Arm Label: Pegylated-interferon Alfa-2a + Ribavirin (Group F); Type: EXPERIMENTAL; Interventions: Drug: Pegylated-interferon Alfa-2a, Drug: Ribavirin | Arm Label: Pegylated-interferon Alfa-2a + Ribavirin (Group NR); Type: EXPERIMENTAL; Interventions: Drug: Pegylated-interferon Alfa-2a, Drug: Ribavirin | Intervention Type: DRUG; Name: Pegylated-interferon Alfa-2a; Assigned to Arm(s): Pegylated-interferon Alfa-2a + Ribavirin (Group A), Pegylated-interferon Alfa-2a + Ribavirin (Group B), Pegylated-interferon Alfa-2a + Ribavirin (Group C), Pegylated-interferon Alfa-2a + Ribavirin (Group D), Pegylated-interferon Alfa-2a + Ribavirin (Group E), Pegylated-interferon Alfa-2a + Ribavirin (Group F), Pegylated-interferon Alfa-2a + Ribavirin (Group NR) | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Pegylated-interferon Alfa-2a + Ribavirin (Group A), Pegylated-interferon Alfa-2a + Ribavirin (Group B), Pegylated-interferon Alfa-2a + Ribavirin (Group C), Pegylated-interferon Alfa-2a + Ribavirin (Group D), Pegylated-interferon Alfa-2a + Ribavirin (Group E), Pegylated-interferon Alfa-2a + Ribavirin (Group F), Pegylated-interferon Alfa-2a + Ribavirin (Group NR)

Answer: B